Prof. Chunfang Hao: Highlights from the Updated CSCO Guidelines for HR+ mBC – A Dual Emphasis on Endocrine Combination Therapy and Precision Testing

Prof. Chunfang Hao: Highlights from the Updated CSCO Guidelines for HR+ mBC – A Dual Emphasis on Endocrine Combination Therapy and Precision Testing

The 2025 National Breast Cancer Conference, held in Beijing from April 11 to 13, featured the highly anticipated update to the CSCO Guidelines for the Diagnosis and Treatment of Breast Cancer (CSCO BC Guidelines). The latest edition further refines stratified treatment strategies and emphasizes the importance of both precision medicine and combination therapies—providing more detailed and practical guidance for clinicians. To explore the key updates, Oncology Frontier invited Prof. Chunfang Hao from the Tianjin Cancer  Hospital (Airport Hospital) to elaborate on recent advances in the endocrine management of hormone receptor-positive (HR+) metastatic breast cancer (mBC).
In-Depth Dialogue with the Chief Medical Officer: Defining AI Boundaries, Breaking Through Resource Equity, and Addressing Professional Burnout

In-Depth Dialogue with the Chief Medical Officer: Defining AI Boundaries, Breaking Through Resource Equity, and Addressing Professional Burnout

As the 2025 Annual Meeting of the National Comprehensive Cancer Network (NCCN) concluded, Oncology Frontier exclusively interviewed Dr. Wui-Jin Koh, Chief Medical Officer of NCCN, to decode the future trends in cancer care. From the application prospects of AI-assisted medical decision-making to the inclusive practice of decentralized clinical trials, from the systemic challenges of combating healthcare professionals' burnout to the ecological reconstruction of cancer patient care systems, Dr. Wui-Jin Koh’s insights not only reveal NCCN’s future directions but also provide valuable references for the global medical community.
ELCC 2025 | Professor Rui Ma on the Final OS Results from the MARIPOSA Study

ELCC 2025 | Professor Rui Ma on the Final OS Results from the MARIPOSA Study

The 2025 European Lung Cancer Congress (ELCC) officially opened on March 26 in Paris, France. On the very first day, during the Proffered Paper Session 1, the highly anticipated final overall survival (OS) results from the MARIPOSA study (Abstract 4O) were presented.Oncology Frontier invited Professor Rui Ma of Liaoning Cancer Hospital to provide an in-depth expert analysis of the updated data and its implications for clinical practice.
ELCC 2025 | Professor Gen Lin: Promising Results for Osimertinib Plus Dato-DXd in TKI-Resistant NSCLC from the ORCHARD Study

ELCC 2025 | Professor Gen Lin: Promising Results for Osimertinib Plus Dato-DXd in TKI-Resistant NSCLC from the ORCHARD Study

At the 2025 European Lung Cancer Congress (ELCC), new data from the ORCHARD study were presented, highlighting the potential of osimertinib in combination with Dato-DXd as a post-progression strategy following first-line osimertinib treatment in patients with EGFR-mutant non-small cell lung cancer (NSCLC). This marks the first public release of efficacy and safety findings for this combination in the treatment of EGFR-TKI resistant NSCLC.
ELCC 2025 | Professor Lin Wu: Long-Term Benefit and Individualized Dose Reduction Strategies of Domestic Third-Generation EGFR-TKI in EGFR T790M-Mutated NSCLC

ELCC 2025 | Professor Lin Wu: Long-Term Benefit and Individualized Dose Reduction Strategies of Domestic Third-Generation EGFR-TKI in EGFR T790M-Mutated NSCLC

At the 2025 European Lung Cancer Congress (ELCC), the team led by Professor Lin Wu from the Hunan Cancer Hospital, Xiangya Hospital, Central South University, presented long-term follow-up data on ASK120067 (rezivertinib) in patients with locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer (NSCLC). Oncology Frontier invited Professor Wu to comment on the key findings and clinical implications of the study for our readers.
ELCC 2025| Professor Wei Zhang on the Optimal Duration of Immunotherapy and Novel Strategies Beyond PD-(L)1 Inhibition

ELCC 2025| Professor Wei Zhang on the Optimal Duration of Immunotherapy and Novel Strategies Beyond PD-(L)1 Inhibition

The recently concluded 2025 European Lung Cancer Congress (ELCC) spotlighted several key clinical topics and unveiled new research with strong translational potential. Oncology Frontier invited Professor Wei Zhang of Shanghai Chest Hospital, Shanghai Jiao Tong University for an in-depth interview, where she shared expert insights on the congress's most impactful themes and dissected the scientific highlights shaping the future of lung cancer treatment.